Sure.. there's classic and then there's modern day
Post# of 148175
It's the ones on the boards, saying that CytoDyn can't make any money off LLMab, the "competition" is too cheap, etc.. there is no competition and cost to manufacture per dose is guaranteed to profit. They know they can't say "it doesn't work" for much longer, so strategy shifts... Like if Nader rejected the low-ball buyout offer, now they're trying to lower expectations so a $20-$30 offer seems reasonable, which, it isn't. That's classic.. "you'll never be worth that."
We will.